Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Plain-language summary

This study evaluates Fludarabine, Mitoxantrone, and Dexamethasone (FND) chemotherapy plus Rituximab in previously untreated patients with advanced indolent (slow-growing) B-cell lymphoma (follicular lymphoma). It included patients younger than 76. It was a Phase 3 study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 3

Status

Completed

Sponsor

M.D. Anderson Cancer Center

Intervention

Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone

Start date

3/16/1998

Estimated completion

8/24/2017

Countries

United States

Related genes

Locations

• Houston, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Previously untreated stage IV indolent B-cell lymphoma \[Amendment May 2001: eligibility restricted to follicular lymphoma\]
2. Age \<76

Exclusion Criteria:

N/A